IP Library Patent Application 14644000
Patent Application
App. No. 14/644,000

Consumable Cryopreserved Cells Transiently Overexpressing Gene(s) Encoding Drug Transporter Protein(s) and/or Drug Metabolizing Enzyme(s)

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/644,000
Abstract

The present invention discloses cryopreserved recombinant cells for screening drug candidates that transiently overexpress one or more drug transporter proteins and/or drug metabolizing enzymes. Advantageously, such cells provide a cost-efficient consumable product that streamlines the process of screening whether drug candidates are substrates or inhibitors of drug transporter proteins and/or drug metabolizing enzymes.

Claims (16)

1 . A cryopreserved recombinant cell comprising one or more transiently overexpressed genes encoding a protein selected from the group consisting of a drug transporter protein and a drug metabolizing enzyme, or a combination thereof wherein activity of the drug transporter protein or the drug metabolizing enzyme or combinations is detectable in a population of the cryopreserved recombinant cell following thaw from cryopreservation.

2 . The recombinant cell of claim 1 , wherein said one or more genes encodes a drug metabolizing enzyme.

3 . The recombinant cell of claim 2 , wherein the drug metabolizing enzyme is selected from the group consisting of cytochrome P450, UDP-glucouronyl transferase, alcohol dehydrogenase, monoamine oxidase and aldehyde oxidase.

4 . The recombinant cell of claim 1 , which transiently overexpresses one or more genes encoding a protein selected from the group consisting of an ATP binding cassette transporter and a solute carrier transporter protein.

5 . The recombinant cell of claim 4 , wherein said one or more genes is selected from the group consisting of MDR1/Mdr1a/Mdr1b, MRP1/Mrp1, MRP2/Mrp2, MRP3/Mrp3, MRP4/Mrp4, MRP5/Mrp5, MRP6/Mrp6, MRP7/Mrp7, MRP 8/Mrp8, BCRP/Bcrp, BSEP/Bsep, OATP2/Oatp2, OATP1B3/Oatp1b3, OAT1/Oat1, OAT2/Oat2, OAT3/Oat3, OAT4/Oat4, OCT1/Oct1, OCT2/Oct2, OATP1/Oatp1, PEPT1/Pept1, PEPT2/Pept2, OCTN1/Octn1, OCTN2/Octn2, MATE1/Mate1, MATE2K/Mate2, URAT1/Urat1, ASBT/Asbt, and NTCP/Ntcp or a combination.

6 . The recombinant cell of claim 4 , wherein said one or more genes is selected from OATP1B1*1a, OATP1B1*1b, OATP1B3, OAT1, OAT3, MATE1 and MATE2K.

7 . The recombinant cell of claim 1 , wherein the one or more genes is derived individually from human or an animal species selected from mouse, rat, guinea pig, dog, and monkey.

8 . The recombinant cell of claim 1 , wherein said cell is selected from the group consisting of HEK293, CHO, MDCK, LLC-PK1, Caco-2 and V79 cells.

9 . The recombinant cell of claim 1 , wherein said cell comprises a hepatocyte.

10 . The recombinant cell of claim 1 , wherein said cell comprises an endothelial cell.

11 . The recombinant cell of claim 1 , wherein activity of the protein(s) is detectable in a population of said cell at least 24 hours post plating following thaw from cryopreservation.

12 . The recombinant cell of claim 1 , wherein activity of the protein(s) is detectable in a population of said cell at least 48 hours post plating following thaw from cryopreservation.

13 . The recombinant cell of claim 1 , wherein activity of the protein(s) is detectable in a population of said cell at least 72 hours post plating following thaw from cryopreservation.

14 . A process of preparing transiently transfected recombinant cells which transiently overexpress one or more genes encoding a protein selected from a drug transporter protein and a drug metabolizing enzyme, comprising transiently transfecting cells with one or more genes encoding a drug transporter protein or a drug metabolizing enzyme and cryopreserving the transiently transfected recombinant cells within 48 hrs of transfection.

15 . The process of claim 14 , wherein the transient transfection step comprises electroporation.

16 . The process of claim 14 , wherein the transiently transfected recombinant cells are cryopreserved at 30 minutes to 24 hours post transfection.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2022
From: CORNING INCORPORATED
To: DISCOVERY LIFE SCIENCES, LLC
Reel/Frame 060197/0485 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2015
From: LI, NA; WANG, JIE; PATTEN, CHRISTOPHER J.
To: CORNING INCORPORATED
Reel/Frame 035131/0812 →